Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) is scheduled to release its earnings data before the market opens on Wednesday, May 8th. Analysts expect Zevra Therapeutics to post earnings of ($0.49) per share for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Thursday, March 28th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.20). Zevra Therapeutics had a negative net margin of 167.69% and a negative return on equity of 68.41%. The company had revenue of $13.22 million for the quarter, compared to the consensus estimate of $13.35 million. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Zevra Therapeutics Trading Up 3.3 %
NASDAQ:ZVRA traded up $0.15 during midday trading on Thursday, hitting $4.75. 125,611 shares of the company traded hands, compared to its average volume of 243,914. The firm has a market capitalization of $206.29 million, a P/E ratio of -3.68 and a beta of 1.87. The firm's fifty day moving average is $5.50 and its 200-day moving average is $5.36. Zevra Therapeutics has a 12-month low of $3.89 and a 12-month high of $7.28. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.08.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on ZVRA shares. Maxim Group raised their target price on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the stock a "buy" rating in a report on Tuesday, April 2nd. Cantor Fitzgerald restated an "overweight" rating on shares of Zevra Therapeutics in a research report on Monday, April 1st. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Zevra Therapeutics in a report on Wednesday, April 3rd. Finally, William Blair restated an "outperform" rating on shares of Zevra Therapeutics in a report on Tuesday, March 12th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zevra Therapeutics has an average rating of "Buy" and an average price target of $19.50.
View Our Latest Stock Analysis on ZVRA
About Zevra Therapeutics
(
Get Free Report)
Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
Further Reading
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
